Epigenetic signaling pathways are implicated in tumorigenesis and therefore histone deacetylases (HDACs) represent novel therapeutic targets for cancers, including multiple myeloma (MM). Although non-selective HDAC inhibitors show anti-MM activities, unfavorable side effects limit their clinical efficacy. Isoform-and/or class-selective HDAC inhibition offers the possibility to maintain clinical activity while avoiding adverse events attendant to broad non-selective HDAC inhibition. We have previously reported that HDAC3 inhibition, either by genetic knockdown or selective inhibitor BG45, abrogates MM cell proliferation. Here we show that knockdown of HDAC3, but not HDAC1 or HDAC2, as well as BG45, downregulate expression of DNA methyltransferase 1 (DNMT1) mediating MM cell proliferation. DNMT1 expression is regulated by c-Myc, and HDAC3 inhibition triggers degradation of c-Myc protein. Moreover, HDAC3 inhibition results in hyperacetylation of DNMT1, thereby reducing the stability of DNMT1 protein.
INTRODUCTION
Histone deacetylases (HDACs)-mediated post-translational modifications represent novel therapeutic targets in various types of cancers, including multiple myeloma (MM). [1] [2] [3] [4] Recently, a nonselective HDAC inhibitor panobinostat was approved by the US Food and Drug Administration (FDA) for the treatment of patients with MM. However, adverse side effects attendant to broad nonselective HDAC inhibitors, such as thrombocytopenia, fatigue and diarrhea, limit their clinical application. 5, 6 To increase tolerability and exploit anti-cancer activity of HDAC inhibitors, isoform-or class-selective HDAC inhibitors are under development. Specifically, we have previously reported that selective genetic or pharmacologic HDAC3 inhibition shows remarkable anti-MM activities in vitro and in vivo in a xenograft mouse model of human MM. 7 However, the molecular mechanisms of action have not yet been delineated.
c-Myc regulates a large number of genes related to cell proliferation and differentiation and is a potent oncogene. 8, 9 MM can develop from a premalignant stage of monoclonal gammopathy of undetermined significance, [10] [11] [12] and during the progression from monoclonal gammopathy of undetermined significance to MM, MYC activation plays a crucial role. [13] [14] [15] Indeed MM cells have been reported to be addicted to c-Myc, which therefore represents a promising therapeutic target in MM. 16 Recent studies have shown that HDACs regulate deacetylation not only of histones, but also of non-histone proteins such as p53 and signal transducer and activator of transcription (STAT3). 17, 18 In terms of post-transrational modification of c-Myc, ubiquitination leads to degradation of the protein. 19 In addition, acetylation of c-Myc by a histone acetyltranferase p300 also triggers proteasomal degradation of c-Myc protein through its ubiquitination. 20 Moreover, HDAC3 interacts with p300 in neuron cells, 21 and HDAC inhibitors, especially class I HDAC inhibitors, can target c-Myc in MM cells. 22, 23 DNA methyltransferase 1 (DNMT1) maintains DNA methylation and is implicated in tumorigenesis. 1, 24, 25 Interestingly, previous studies have shown that HDAC1 forms a complex with DNMT1, 26 and that the protein stability of DNMT1 is regulated by post-translational modifications of acetylation and ubiquitination. 27, 28 Importantly, the binding of DNMT1 with ubiquitin-specific peptidase 7 (USP7, also known as HAUSP) is regulated by the acetylation of DNMT1. 28 However, it is not yet known which HDAC isoform specificity mediates regulation of c-Myc deacetylation or regulates interaction between DNMT1 and USP7.
In the present study, we first demonstrate that HDAC3 inhibition leads to downregulation of c-Myc, in turn resulting in downregulation of DNMT1 mRNA expression. Furthermore, we demonstrate that HDAC3 forms a complex with DNMT1, and that HDAC3 inhibition results in an increased acetylation of DNMT1 and leads to degradation of DNMT1. Finally, we show that combination inhibition of DNMT1 and HDAC3 triggers synergistic MM growth inhibition in vitro and in in vivo in a murine xenograft model of human MM, providing the framework for clinical evaluation of this combination therapy.
MATERIALS AND METHODS
No statistical analysis was used to predetermine sample size. The experiments were not randomized and the investigators were not blinded 1 to allocation during experiments and outcome assessment. For a more detailed description of the methods used, see Supplementary Materials and Methods.
RESULTS

HDAC3 regulates c-Myc
Since prior studies have shown that HDAC inhibitors, especially class I HDAC inhibitors, downregulate c-Myc, 22, 23 we first examined whether HDAC3-selective inhibition triggers downregulation of c-Myc expression using an HDAC3-selective small molecule inhibitor BG45. As expected, BG45 treatment is associated with decreased c-Myc in MM.1S, RPMI 8226 and NCI-H929 (H929) cells in time-and dose-dependent manners (Figure 1a and Supplementary Figure S1a ). However, mRNA levels were not altered by the treatment (Supplementary Figure S1a) . To confirm whether c-Myc downregulation was solely due to HDAC3 inhibition, we carried out HDAC3 knockdown in MM.1S, RPMI 8226 and H929 cells using lentiviral short-hairpin RNAs (shRNAs) targeting HDAC3 (shHDAC3 #1 and #2) or control shRNAtargeting luciferase (shLuc). Consistent with BG45 treatment, c-Myc was markedly downregulated in HDAC3-knockdown MM cells ( Figure 1b ), without significant alteration of MYC mRNA (Supplementary Figure S1b) . Moreover, c-Myc was significantly decreased in BG45-treated MM.1S cells in the presence of cycloheximide (CHX), further suggesting that downregulation of c-Myc by HDAC3 inhibition is not due to inhibition of transcription ( Figure 1c ). Importantly, hyperacetylated c-Myc was detected in MM.1S cells treated with BG45 ( Figure 1d ). A previous study has shown that treatment with non-selective HDAC inhibitors lead to acetylation of c-Myc due to inhibition of deacetylases, resulting in degradation of c-Myc by proteasome. 20 Our results therefore suggest that HDAC3 inhibition has an important role in hyperacetylation of c-Myc, followed by its degradation. Taken together, these results suggest that HDAC3 regulates c-Myc protein level, rather than modulating transcription.
HDAC3 regulates DNMT1
To identify the target molecules of HDAC3, we next carried out gene expression profiling using MM.1S cells transduced with shHDAC3 (#1 and #2) or shLuc. A total of 397 genes were down-or upregulated (adjusted P-value o0.001, log fold change 40.5) in HDAC3-knockdown cells compared to control cells ( Supplementary Table S5 ). We have previously reported that HDAC3 knockdown induces apoptosis in MM cells. 7 Consistent with this observation, knockdown of HDAC3 markedly decreased expression of XIAP and Bcl-2, the members of the inhibitor of apoptosis family of proteins ( Supplementary Table S5 and Supplementary Figure S2 ). Since HDAC has a crucial role in epigenetic modulation, we here focused on epigenetic regulators implicated in tumor pathogenesis. 1, 2 Out of the 423 epigenetic regulators defined by Gene Ontology, DNMT1 was most significantly downregulated in HDAC3-knockdown cells (Figure 2a and Supplementary Table S5 ).
Downregulation of DNMT1 by HDAC3 knockdown was confirmed by quantitative real-time PCR (Q-PCR) (Supplementary Figure S3a ). We further confirmed downregulation of DNMT1 protein expression in HDAC3-knockdown MM.1S, RPMI 8226 and H929 cells with immunoblotting ( Figure 2b ). Importantly, HDAC3 knockdown, but not HDAC1 or HDAC2 knockdown, significantly downregulated DNMT1 expression ( Figure 2c ). Consistent with the results of HDAC3-knockdown, DNMT1 was downregulated after BG45 treatment in MM.1S, RPMI 8226, and H929 cells (Figures 2d and e, and Supplementary Figure S3b ). DNMT1 expression was also reduced after treatment with non-selective HDAC inhibitor LBH-589, or with HDAC1 and 3 selective inhibitor MS-275, but was not affected by treatment with HDAC1 and HDAC2 selective inhibitor Merck60 (Figure 2f ), further confirming that both genetic and pharmacological inhibition of HDAC3 trigger downregulation of DNMT1 expression in MM cells.
We next examined the effect of DNMT1 downregulation on MM cell growth. Growth of MM.1S, RPMI 8226, and H929 MM cell lines transduced with shRNAs targeting DNMT1 (shDNMT1 #1 and #2), but not shLuc, was significantly inhibited, associated with Figure S4a ). We observed cleavage of caspase-3 and poly (ADPribose) polymerase (PARP), suggesting that DNMT1 knockdown induces apoptotic cell death (Supplementary Figure S4b ). Taken together, these results suggest that DNMT1 downregulation mediates, at least in part, HDAC3 inhibition-induced MM cell growth inhibition.
downregulation of DNMT1 expression (Supplementary
c-Myc regulates DNMT1
Since HDAC3 inhibition downregulates both c-Myc and DNMT1, we hypothesized that c-Myc may regulate DNMT1 expression. We therefore next analyzed the occupancy of c-Myc at the DNMT1 locus using publicly available ChIP-Seq data (GSE36354) (Figure 3a ). 29 As expected, there was a significant occupancy of c-Myc at the DNMT1 locus, and the majority of c-Myc binding sites were localized around intron 1 of DNMT1 (Figure 3a ). We next validated ChIP-seq results by ChIP-Q-PCR. Among the four enriched regions at the DNMT1 locus identified by ChIP-seq, sequences of regions at introns 1 and 9 were recovered at a high level in the c-Myc antibody immunoprecipitate compared to that of control IgG (Supplementary Figure S5a ). Furthermore, these ChIP signals were reduced in MYC-knockdown MM.1S cells (Supplementary Figure S5a) , confirming c-Myc binding at these regions. We further confirmed downregulation of DNMT1 mRNA level and protein expression in MM.1S and RPMI 8226 cells transduced with shRNAs targeting MYC (Figure 3b and Supplementary Figure S5b ). Consistent with these results, there is a positive correlation between expression of MYC and DNMT1 in primary myeloma samples in publicly available data (GSE6477 and GSE19784) (Supplementary Figure S5c) . Taken together, these results indicate that c-Myc transcriptionally regulates DNMT1 in MM cells. HDAC3 regulates DNMT1 in MM HDAC3 regulates DNMT1 protein stability through its acetylation Since previous studies have shown that protein stability of DNMT1 is regulated through its acetylation and subsequent ubiquitination, 27, 28 we next examined whether HDAC3 inhibition triggers acetylation and regulates protein stability of DNMT1. We first showed that protein stability of DNMT1 in MM.1S cells was significantly decreased after treatment with BG45 in the presence of CHX (Figure 4a ). Since previous studies have shown that DNMT1 forms a complex with HDAC1 or USP7, [26] [27] [28] we next examined whether HDAC3 physically interacts with DNMT1. Importantly, we observed that DNMT1 co-immunoprecipitated not only with USP7 but also with HDAC3 ( Supplementary Figure S6) , indicating that HDAC3, DNMT1 and USP7 form a complex. We also assessed whether HDAC3 inhibition modulates this complex formation: acetylation and ubiquitination of DNMT1 was increased in BG45treated MM.1S cells, associated with decreased binding between DNMT1 and USP7 (Figure 4b ).
We further examined the effect of HDAC3 on ubiquitination of DNMT1 using a deubiquitination assay in 293T cells. Importantly, both HDAC3 and USP7 decreased DNMT1 ubiquitination (Figure 4c, DNMT1 IP) . In contrast, DNMT1 protein level was increased in the presence of HDAC3 and USP7 (Figure 4c Input). A previous report has shown that acetylation of Lysine (K1111/ K1113/K1115/K1117) is required for ubiquitination of DNMT1. 28 Consistent with this report, mutations of these acetylation sites abrogated ubiquitination of DNMT1 (Figure 4d ). These results suggest that HDAC3 promotes stability of DNMT1, whereas HDAC3 inhibition induces DNMT1 ubiquitination, followed by its degradation by proteasomes.
Taken together, HDAC3 modulates DNMT1 mRNA expression through the regulation of c-Myc protein stability. Furthermore, HDAC3 also deacetylates and stabilizes DNMT1 protein. Our results indicate that HDAC3 regulates DNMT1 expression by modulating transcription and protein stability (Figure 4e ).
Pharmacological inhibition of HDAC3 and DNMT1 synergistically inhibits MM cell growth in vitro as well as in vivo 5-Azacytidine (AZA) is used as a DNMT1 inhibitor in the treatment of acute myeloid leukemia and myelodysplastic syndrome. 30 Since previous reports have also shown anti-MM activity of AZA, 31, 32 we examined whether HDAC3 inhibitor with AZA induces synergistic DNMT1 inhibition and MM cell growth inhibition. We first evaluated the effect of AZA on DNMT1 protein expression in MM cells. Consistent with the previous reports, AZA downregulated DNMT1 expression in dose-and time-dependent manners (Supplementary Figure S7a) . Importantly, BG45 with AZA markedly reduced DNMT1 in MM.1S and RPMI8226 cells (Supplementary Figure S7b) , associated with synergistic cell growth inhibition and increased cleavage of caspase-3, -8, -9 and PARP ( Supplementary Figures S7c and S7d , and Supplementary Table S6 ). Similar results were observed in primary tumor cells from MM patients ( Supplementary Figures S7e and f) . We next evaluated this combination treatment in vivo using a murine xenograft model of human MM. At day 25 of treatment, significant tumor growth inhibition was observed in mice treated with BG45 or AZA alone compared to the vehicle control group (P = 0.021 and P = 0.005, respectively) ( Figure 5a ). Importantly, BG45 with AZA enhanced tumor growth inhibition compared to monotherapy cohorts (P = 0.001 in AZA versus the combination, and P = 0.003 in BG45 versus the combination), without significant body weight loss (Supplementary Figure S8a) . Representative images of tumor growth inhibition by the combination treatment are shown in Figure 5b . The median OS of the combination treated cohort (45 days) was significantly prolonged compared to vehicle or monotherapy treated cohorts (P = 0.0002 in vehicle versus the combination, P = 0.0006 in AZA versus the combination, and P = 0.0002 in BG45 versus the combination) (Supplementary Figure S8b ). Consistent with our in vitro experiments, c-Myc and DNMT1 was decreased in tumor harvested from the BG45-treated or combination treated cohort ( Supplementary Figures S8c and d) .
These results indicate that AZA and BG45 in combination enhance in vivo cell growth inhibition through targeting DNMT1.
DISCUSSION
HDACs have numerous target molecules, which are not only histones but also non-histone proteins, including transcription factors. 17, 18 We have previously reported that HDAC3 targets STAT3, and that inhibition of HDAC3 dephospholylates STAT3, thereby reducing MM cell growth. 7 In this study, we further examined the mechanisms whereby HDAC3 inhibition abrogates MM cell growth, and show that HDAC3 targets c-Myc and DNMT1. c-Myc is a potent oncoprotein which has a critical role in progression of monoclonal gammopathy of undetermined significance to MM. [13] [14] [15] Previous reports have shown that HDAC inhibitors downregulate c-Myc expression; 22, 23 however, the effect of HDAC isoform-selective inhibition on c-Myc modulation has not yet been elucidated. Here we show that HDAC3 inhibition triggers downregulation of c-Myc protein level, without alteration of mRNA level.
Previous reports have shown that HDAC inhibitors target DNMT1 in various cancer cell types; 27, 28, 33 however, which HDAC isoform (s) regulate DNMT1 expression has not been defined. In addition, prior studies have suggested that HDACs regulate protein stability, but not transcription, of DNMT1. 27, 28, 33 In this study, our microarray analysis and Q-PCR show that HDAC3 regulates DNMT1 mRNA expression in MM cells. Importantly, we demonstrate that c-Myc regulates DNMT1 expression, confirming that HDAC3 regulates DNMT1 mRNA expression via its effects on protein stability of c-Myc. Of note, DNMT1 expression is not solely mediated by c-Myc and/or HDAC3. Indeed, DNMT1 expression can be regulated by other signaling pathways. For example, it is also modulated via Rb/E2F or p53/SP1 cascade at the transcriptional level. 34, 35 We therefore carried out knockdown of E2F1 and SP1, but noted no significant change in DNMT1 protein expression in MM.1S cells (Supplementary Figure S9) . These results suggest that c-Myc is a key factor maintaining DNMT1 expression in MM cells. DNMT1 protein expression is regulated by its protein stability via its acetylation and ubiquitination status. 27, 28, 36 For example, USP7 has been shown to deubiquitinate DNMT1, 27, 28 and a recent study by Cheng et al. 28 has demonstrated that protein stability of DNMT1 is mediated by binding of USP7, a physical interaction regulated by DNMT1 acetylation. However, this study did not identify which HDAC isoform impacts DNMT1 deacetylation. In our study, we demonstrate that HDAC3 is associated with deacetylation of DNMT1, followed by decreased ubiquitination and degradation of DNMT1, indicating that HDAC3 regulates DNMT1 protein stability via its deacetylation.
A recent study has shown that DNMT1 is an essential factor not only for mammary but also cancer stem cell maintenance and tumorigenesis. 37 Our current study demonstrates that DNMT1 is also essential for MM cell survival. To reveal the downstream targets of DNMT1 in MM cells, we performed gene expression profiling after knockdown of DNMT1 in MM.1S cells ( Supplementary Table S7 ). Gene set enrichment analysis revealed that genes encoding regulators of cell cycle were significantly reduced after knockdown of DNMT1 (Supplementary Figure S10a) . We then confirmed that knockdown of DNMT1 leads to S-phase cell cycle arrest in MM.1S cells (Supplementary Figure S10b) . These data suggest that DNMT1 is an important cell cycle regulator in MM cells.
Class I or II HDACs are attractive therapeutic targets in MM. In particular, a large number of HDAC inhibitors target mainly class I HDACs (especially HDAC1, 2, 3) and IIb HDACs (HDAC6). 38 Our previous report validates genetic knockdown or pharmacological inhibition of HDAC3 as a novel potential therapeutic strategy in MM. 7 Although non-selective HDAC inhibitors induce anti-MM activity, they also have attendant unfavorable side effects. 5, 6 Moreover, HDAC inhibitor monotherapy induces only modest anti-MM clinical activity. 39, 40 To reduce unfavorable toxicities and augment the anti-tumor effect of HDAC inhibitors, we therefore need to develop more tolerable HDAC inhibitors that can be used in combination. Our previous study has demonstrated that the combination of BG45 and a proteasome inhibitor bortezomib induces synergistic cytotoxicity against MM cells. 7 Here we show that knockdown of HDAC3, as well as HDAC3 inhibition by BG45, markedly decrease the expression of members of the inhibitor of apoptosis family of proteins XIAP and Bcl-2 (Supplementary Figure S2) . Thus, the combination of BG45 with bortezomib may synergistically augment apoptotic signaling pathways. Regarding DNMT1, previous studies have shown that the combination of non-selective HDAC inhibitors with DNMT inhibitors are effective treatment of cancers. 30, 31 Importantly, our study shows that BG45 in combination with AZA markedly downregulates DNMT1, triggers synergistic anti-MM activity in vitro, as well as significantly inhibits in vivo tumor cell growth in a murine xenograft mouse model of human MM.
Taken together, we demonstrate that HDAC3 inhibition reduces DNMT1 expression via regulation of mRNA and protein levels; and importantly, that HDAC3 inhibitor and DNMT1 inhibitor induces synergistic anti-MM activity. Our results therefore provide the rationale for combination treatment with HDAC3 inhibitor and DNMT1 inhibitor to improve patient outcome in MM.
